Roche has announced that NICE has issued its final decision to recommend the use of its Gazyvaro (obinutuzumab). The glyco-engineered Type II anti-CD20 monoclonal antibody will now be available on the NHS when used in combination with chemotherapy for the treatment of previously untreated advanced follicular lymphoma (FL) in patients who are at higher risk of relapse, followed by obinutuzumab maintenance.
NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma
